

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

**INSIDE INFORMATION
REGISTRATION OF MEDIUM TERM NOTES
BY THE NATIONAL ASSOCIATION OF
FINANCIAL MARKET INSTITUTIONAL INVESTORS**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of China Resources Pharmaceutical Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that China Resources Pharmaceutical Holdings Company Limited (華潤醫藥控股有限公司) (“**CR Pharmaceutical Holdings**”), a wholly-owned subsidiary of the Company, has received a notice of acceptance of registration (Zhong Shi Xie Zhu [2018] No. MTN429) (the “**Notice**”) issued by the National Association of Financial Market Institutional Investors in relation to the proposed issuance of Medium-Term Notes (the “**Medium Term Notes**”) of up to RMB12 billion by CR Pharmaceutical Holdings in the People’s Republic of China (the “**PRC**”). The Notice shall be effective for a period of two years from the issue date of the Notice, during which CR Pharmaceutical Holdings may issue the Medium Term Notes in tranches. If the proposed issuance of the Medium Term Notes proceeds, it is expected that the proceeds raised therefrom will mainly be used for the replenishment of working capital of China Resources Pharmaceutical Commercial Group Company Limited (華潤醫藥商業集團有限公司), an indirect wholly-owned subsidiary of CR Pharmaceutical Holdings.

The Company will make further announcement in relation to the proposed issuance of the Medium Term Notes as and when appropriate.

As the proposed issuance of the Medium Term Notes may or may not proceed, shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Executive Director

Beijing, 17 August 2018

As of the date of this announcement, the Board comprises Mr. FU Yuning as chairman and non-executive Director, Mr. WANG Chuncheng and Mr. LI Guohui as executive Directors, Mr. CHEN Rong, Mr. YU Zhongliang, Mr. WANG Shouye and Mr. LU Ruizhi as non-executive Directors, Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.